There are 18 resources available
1088MO - A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up
Presenter: Neil Gross
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA47 - A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
Presenter: Alan Ho
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
857O - MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)
Presenter: Pierre Blanchard
Session: Proffered Paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
854O - INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)
Presenter: Jérome Fayette
Session: Proffered Paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
856MO - A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis
Presenter: Dan Zandberg
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
557MO - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Clelia Coutzac
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
LBA46 - SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy
Presenter: Nicolas Mach
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
1020MO - AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity
Presenter: Feng Wang
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast